ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to collect initial efficacy and safety data on the use of a new
treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard
chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment
with pemetrexed alone